Biotesserae Camunity develops a nanobody-based platform designed for canine cancer treatments.
Biotesserae Camunity is a nanobody-based platform for the production of a new class of therapeutics for canine cancer. The company was formed by Chris Cebra, chair of the Department of Clinical Sciences, and colleagues Shay Bracha, Dan Mourich, and Carl Ruby.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 6, 2022 | Pre-seed | $100K | 1 | EXPERT DOJO | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
EXPERT DOJO | Yes | Pre-seed |